The field of complement drug discovery has never been riper with opportunities for therapeutic intervention in diverse clinical indications. Over the past few years, we have witnessed a true resurgence of complement therapeutics in an evolving clinical landscape, shaped by a series of game-changing mechanistic, translational and clinical developments. The recent clinical approvals of a set of mechanistically distinct complement inhibitors targeting the initiation routes, the central step of C3 activation or downstream terminal effector signaling have expanded the clinical arsenal of complement therapeutics bringing tailored complement intervention closer to fruition. These developments have also bolstered confidence in the safety and broader therapeutic scope of complement inhibition. In fact, a multitude of drug candidates are advancing through late-stage clinical development as treatment options for various indications. At the same time, pathway-specific complement modulators serve as elegant molecular tools for dissecting the contribution of aberrant complement signaling to disease pathology.
Embracing these exciting developments, we are delighted to announce the 17th International Conference on Complement Therapeutics in Sissi, Crete which will bring together leading experts and innovators from both academia and industry to share new data and discuss the latest developments in therapeutic design, clinical trials and new aspects of complement-driven pathophysiology in emerging indications. Topics will include: Structural insights and mechanisms of complement activation and regulation, New therapeutic targets in complement-mediated diseases; Novel complement inhibitors & pipeline compounds; Hematological disorders; Organ & cell transplantation, I/R injury and chronic rejection; Kidney diseases; Neurological & ocular diseases; Acute and chronic inflammatory disorders; Infectious diseases & COVID-19; complement targeting in cancer immunotherapy; complement biomarkers in disease diagnosis and therapy; Novel and unexpected indications
